TPCW
BMRN icon

TD Private Client Wealth’s BioMarin Pharmaceuticals BMRN Stock Holding History

TD Private Client Wealth’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.09K Buy
89
+86
+2,867% +$4.71K ﹤0.01% 1213
2026
Q1 		$169 Hold
3
– – ﹤0.01% 1589
2025
Q4 		$178 Buy
+3
New +$163 ﹤0.01% 1544
2025
Q3 		– Sell
-504
Closed -$27.7K – 1540
2025
Q2 		$27.7K Sell
504
-178
-26% -$10.5K ﹤0.01% 941
2025
Q1 		$48.2K Buy
682
+46
+7% +$3.1K ﹤0.01% 819
2024
Q4 		$41.8K Buy
636
+126
+25% +$8.44K ﹤0.01% 856
2024
Q3 		$35.8K Buy
510
+186
+57% +$15.5K ﹤0.01% 888
2024
Q2 		$26.7K Buy
324
+75
+30% +$6.24K ﹤0.01% 907
2024
Q1 		$21.7K Buy
249
+108
+77% +$9.67K ﹤0.01% 939
2023
Q4 		$13.6K Buy
141
+24
+21% +$2.12K ﹤0.01% 1010
2023
Q3 		$10.4K Buy
117
+11
+10% +$979 ﹤0.01% 1026
2023
Q2 		$9.19K Buy
106
+26
+33% +$2.45K ﹤0.01% 1064
2023
Q1 		$7.78K Buy
80
+14
+21% +$1.45K ﹤0.01% 1064
2022
Q4 		$6.83K Buy
66
+10
+18% +$939 ﹤0.01% 1053
2022
Q3 		$4.75K Hold
56
– – ﹤0.01% 1063
2022
Q2 		$4.64K Hold
56
– – ﹤0.01% 1080
2022
Q1 		$4.32K Sell
56
-14
-20% -$1.17K ﹤0.01% 1109
2021
Q4 		$6.18K Buy
70
+30
+75% +$2.48K ﹤0.01% 942
2021
Q3 		$3.09K Sell
40
-8
-17% -$631 ﹤0.01% 996
2021
Q2 		$4K Buy
48
+11
+30% +$872 ﹤0.01% 977
2021
Q1 		$2.79K Buy
37
+15
+68% +$1.23K ﹤0.01% 980
2020
Q4 		$1.93K Buy
22
+4
+22% +$317 ﹤0.01% 961
2020
Q3 		$1.37K Buy
18
+10
+125% +$1.01K ﹤0.01% 941
2020
Q2 		$987 Sell
8
-27
-77% -$2.68K ﹤0.01% 960
2020
Q1 		$2.96K Hold
35
– – ﹤0.01% 849
2019
Q4 		$2.96K Buy
+35
New +$2.64K ﹤0.01% 871

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

TD Private Client Wealth's BMRN Position: Q2 2026 in Review

TD Private Client Wealth increased its BioMarin Pharmaceuticals (BMRN) stake by 2,867% in Q2 2026, buying an estimated $4.71K and bringing the position to 89 shares worth $5.09K. The position accounts for ﹤0.01% of the portfolio, ranked #1213.

TD Private Client Wealth first reported a position in BMRN in Q4 2019 and has held it in 26 quarters since. The position peaked at $48.2K in Q1 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • TD Private Client Wealth held 89 shares of BioMarin Pharmaceuticals worth $5.09K as of Q2 2026.
  • TD Private Client Wealth bought 86 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $4.71K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of TD Private Client Wealth's portfolio in Q2 2026, its #1213 holding.
  • TD Private Client Wealth first reported a position in BioMarin Pharmaceuticals in Q4 2019 and has held it in 26 quarters since.
  • TD Private Client Wealth's BioMarin Pharmaceuticals position peaked at $48.2K in Q1 2025.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on TD Private Client Wealth's 13F filing for Q2 2026, filed 4 Aug 2026.